Lower-priced insulin from Lilly now available in USA

US pharma major Eli Lilly (NYSE: LLY) says that its previously-announced lower-priced Insulin Lispro Injection is now available for order in US pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option.

Lilly's Insulin Lispro Injection has a 50% lower list price than its identical medicine, Humalog U-100 (insulin lispro injection) and is available in both a vial and KwikPen. Because they are the same insulin, pharmacists will be able to substitute Insulin Lispro Injection for Humalog.

Following heavy criticism of high insulin prices in the USA, in March, Lilly announced plans to introduce Insulin Lispro Injection, which fills another gap in the healthcare system. The people who are most likely to benefit from Insulin Lispro Injection are Medicare Part D beneficiaries, people with high-deductible health plans and the uninsured who use Humalog.